COMMUNIQUÉS West-GlobeNewswire

Anavex Life Sciences Presented at the 6th Annual European Rett Syndrome Conference Preliminary Clinical Efficacy Data from the U.S. Rett Syndrome Phase 2 ANAVEX®2-73 Study

27/09/2019 - 09:00

NEW YORK, Sept. 27, 2019 (GLOBE NEWSWIRE) -- Anavex Life Sciences Corp. (“Anavex” or the “Company”) (Nasdaq: AVXL), a clinical-stage biopharmaceutical company developing differentiated therapeutics for the treatment of [...]

Nexstim New System Sales Update

27/09/2019 - 08:30

Press Release, Helsinki, 27 September 2019 at 9.30 am (EET) Nexstim New System Sales Update Nexstim Plc (NXTMH:HEX, NXTMS:STO) ("Nexstim" or "Company")—the company developing and marketing a unique brain stimulation [...]

Kymab Outlines Positive New Findings for its KY1044 Anti-ICOS Program at the CICON 2019 Annual Meeting

27/09/2019 - 08:00

Kymab Outlines Positive New Findings for its KY1044 Anti-ICOS Program at the CICON 2019 Annual Meeting KY1044 increases the ratio of intratumoral cytotoxic-to-regulatory T cells and induces tumor regression Expanding [...]

Nicox Completes Enrolment of NCX 4251 Phase 2 Trial with Top-Line Results on Track for Q4 2019

27/09/2019 - 07:30

Press Release Nicox Completes Enrolment of NCX 4251 Phase 2 Trial with Top-Line Results on Track for Q4 2019 September 27, 2019 – release at 7:30 am CET Sophia Antipolis, France Nicox SA (Euronext Paris: FR0013018124, [...]

Nicox : Recrutement terminé dans l’étude clinique de phase 2 pour le NCX 4251 – Premiers résultats attendus au quatrième trimestre 2019

27/09/2019 - 07:30

Communiqué de presse Nicox : Recrutement terminé dans l’étude clinique de phase 2 pour le NCX 4251 – Premiers résultats attendus au quatrième trimestre 2019 27 septembre 2019 – diffusion à 7h30 Sophia Antipolis, France [...]

ObsEva SA to Participate in Cantor Global Healthcare Conference October 2-4, 2019

27/09/2019 - 07:00

Geneva, Switzerland and Boston, MA – September 27, 2019 - ObsEva SA (NASDAQ: OBSV / SIX: OBSN), a clinical-stage biopharmaceutical company focused on the development and commercialization of novel therapeutics for [...]

Bone Therapeutics to present data from its Phase II/III trial with JTA-004 at the 2nd World Congress on Rheumatology & Orthopedics

27/09/2019 - 07:00

Press release Gosselies, Belgium, 27 September 2019, 7am CEST – BONE THERAPEUTICS (Euronext Brussels and Paris: BOTHE), the leading biotech company focused on the development of innovative cell and biological therapies [...]

Bone Therapeutics présentera les données cliniques de la phase II/III de l’essai évaluant JTA-004 à l’occasion du 2ème Congrès Mondial de Rhumatologie et d’Orthopédie (WCRO)

27/09/2019 - 07:00

Communiqué de presse Gosselies, Belgique, le 27 septembre 2019, 07h00 CEST – BONE THERAPEUTICS (Euronext Bruxelles et Paris : BOTHE, éligible PEA-PME), société de biotechnologie spécialisée dans le développement de [...]

MDxHealth Successfully Completes a EUR 9.0 Million (USD 9.8 Million)(1) Capital Increase

27/09/2019 - 06:00

Press release Regulated information – Inside information 27 September 2019, 6:00 a.m. CEST IRVINE, CA, and HERSTAL, BELGIUM – 27 September 2019 – MDxHealth SA (Euronext Brussels: MDXH) (the " Company " or " MDxHealth [...]

MDxHealth Réalise avec Succès une Augmentation de Capital à Hauteur de € 9,0 Millions ($ 9,8 Millions)(1)

27/09/2019 - 06:00

C ommuniqué de presse Information règlementée - Information privilégiée 27 septembre 2019, 06H00 HEC I RVINE, CA, et HERSTAL (BELGIQUE) – le 27 septembre 2019 – MDxHealth SA (Euronext Brussels: MDXH) (la " Société [...]

Resverlogix to Host BETonMACE Webcast and Conference Call

27/09/2019 - 01:04

CALGARY, Alberta, Sept. 26, 2019 (GLOBE NEWSWIRE) -- Resverlogix Corp. (“Resverlogix” or the "Company") (TSX: RVX) today announces that, in connection with BETonMACE topline results, expected to be announced on [...]

Calithera to Host Webcast Conference Call for Analysts and Investors During European Society for Medical Oncology (ESMO) Congress 2019

27/09/2019 - 00:05

- Call and audio webcast will take place Monday, Sept. 30 at 8:30 a.m. Eastern Time - SOUTH SAN FRANCISCO, Calif., Sept. 26, 2019 (GLOBE NEWSWIRE) -- Calithera Biosciences, Inc. (Nasdaq: CALA), a clinical-stage [...]

BeiGene Announces Clinical Data on Tislelizumab and Pamiparib to Be Presented at the European Society for Medical Oncology (ESMO) Congress 2019

27/09/2019 - 00:05

CAMBRIDGE, Mass. and BEIJING, China, Sept. 26, 2019 (GLOBE NEWSWIRE) -- BeiGene, Ltd. (NASDAQ: BGNE; HKEX: 06160), a commercial-stage biopharmaceutical company focused on developing and commercializing innovative [...]

Adverum Biotechnologies to Present Additional Clinical Data from First Cohort of OPTIC Phase 1 Trial of ADVM-022 Intravitreal Gene Therapy to Treat Wet AMD at the American Academy of Ophthalmology 2019 Annual Meeting

26/09/2019 - 23:25

Company to Host and Webcast a Discussion with Key Opinion Leaders on Saturday, October 12 at 10:30 am PT MENLO PARK, Calif., Sept. 26, 2019 (GLOBE NEWSWIRE) -- Adverum Biotechnologies, Inc. (Nasdaq: ADVM), a clinical- [...]

IntelGenx Announces Resubmission of RIZAPORT® New Drug Application

26/09/2019 - 22:34

SAINT LAURENT, Quebec, Sept. 26, 2019 (GLOBE NEWSWIRE) -- IntelGenx Corp. (TSX-V:IGX)(OTCQX:IGXT) (the "Company" or "IntelGenx"), a leader in pharmaceutical films, today announced that it has resubmitted its 505(b)(2) [...]

Inspire Medical Systems, Inc. Announces Additional Draft Local Coverage Determinations Proposing Coverage of Inspire Therapy

26/09/2019 - 22:30

National Government Services and CGS Administrators, collectively representing 12 states, issue draft policies initiating open public comment period MINNEAPOLIS, Sept. 26, 2019 (GLOBE NEWSWIRE) -- Inspire Medical [...]

Retrophin to Present at the 2019 Cantor Global Healthcare Conference

26/09/2019 - 22:30

SAN DIEGO, Sept. 26, 2019 (GLOBE NEWSWIRE) -- Retrophin, Inc. (NASDAQ: RTRX) today announced that Eric Dube, Ph.D., chief executive officer, will present at the 2019 Cantor Global Healthcare Conference in New York City [...]

Arbitration Decision Affirms Intellia Therapeutics’ Interpretation of Licensing Agreement with Caribou Biosciences on the CRISPR/Cas9 Technology

26/09/2019 - 22:30

Interim Award concluded all technology in dispute was exclusively licensed to Intellia Parties must negotiate terms and payments to Intellia for Caribou’s use of the chemically modified guide RNAs CAMBRIDGE, Mass., Sept [...]

CorMedix Inc. to Present at the Cantor 2019 Global Healthcare Conference

26/09/2019 - 22:30

BERKELEY HEIGHTS, N.J., Sept. 26, 2019 (GLOBE NEWSWIRE) -- CorMedix Inc. (NYSE American: CRMD), a biopharmaceutical company focused on developing and commercializing therapeutic products for the prevention and treatment [...]